Vilon is among the smallest biologically active peptides, studied mainly in Russia to support the aging immune system and slow age-related decline. Nearly all evidence comes from a single research group, much of it in animals, and rarely independently confirmed. No approved products outside Russia, no long-term safety data, no registered trials — an intriguing but largely unproven idea. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Lymphocyte subsets (CD4, CD8, CD4:CD8 ratio) | CD4:CD8 ratio ~1.5–2.5 | Tracks the immune (thymic) effect Vilon is proposed to have |
| Complete blood count with differential | Lymphocytes ~20–40% | Detects broad immune and blood changes and any suppression |
| Immunoglobulin A (IgA) | ~70–400 mg/dL | Reported to normalize in the human studies; marker of mucosal immunity |
| Coagulation panel (PT/INR, aPTT, fibrinogen) | INR ~0.9–1.1; fibrinogen ~200–400 mg/dL | Vilon reportedly shifts clotting balance; essential with blood thinners |
| High-sensitivity C-reactive protein (hs-CRP) | <1.0 mg/L | General gauge of systemic inflammation and immune activation |
Cadence: Baseline, then after the first 10-day course, then every 6–12 months if courses are repeated; additional clotting checks if blood thinners are co-used